Risk of studydefined symptomatic intracranial haemorrhage after acute ischaemic stroke reperfusion therapy in atrial fibrillation (AF)
| Cardiac condition Reference name (number) (sICH timing) | Reperfusion type | Effect estimate (95% CI)* |
| Atrial fibrillation | ||
| AF versus no AF w/o additional risk factors | ||
| Frank et al, 201211 (<72 hours) | Intravenous rtPA | OR 1.20 (0.66 to 2.18) |
| Yue et al, 201614 (1−8 days) | Intravenous rtPA | OR 1.28† (1.08 to 1.52) |
| Nogueira et al, 201517 (24–36 hours) | Intravenous rtPA and/or ET | OR 1.61 (1.01 to 2.55) |
| Smaal et al, 202015 (<90 days) | Intravenous rtPA and/or ET | OR 0.57 (0.3 to 1.07) |
| Akbik et al, 202016 (<24 hours) | Intravenous rtPA and/or ET | OR 0.76 (0.49 to 1.18) |
| On warfarin | ||
| Zhao et al, 201639 (<24 hours) | Intravenous rtPA | OR 6.31† (1.18 to 33.87) |
| With heartfailure | ||
| Zhao et al, 201639 (<24 hours) | Intravenous rtPA | OR 1.54 (0.64 to 3.71) |
| With high NIHSS (>20) at admission | ||
| Zhao et al, 201639 (<24 hours) | Intravenous rtPA | OR 1.10† (1.03 to 1.17) |
*CIs were not reported for all studies
†Denotes statistical significance under the p<0.05 assumption.
d, days; ET, endovascular therapy (eg, arterial thrombectomy); h, hours; NIHSS, National Institutes of Health Stroke Scale; ; IV rtPA, intravenous recombinant tissue plasminogen activator; sICH, symptomatic intracranial haemorrhage; w/o, without.